Posts

Recent Pharma News: Novo Nordisk's Oral Semaglutide for Kids, Altimmune $225M Offering, Merck-Google Cloud Partnership

on
Novo Nordisk announced positive Phase 3a trial results for oral semaglutide on April 23, 2026, showing superior blood sugar reduction in children and adolescents with diabetes compared to placebo. 1 The trial demonstrated the pill lowers blood sugar effectively in young patients with diabetes, with plans to seek regulatory approval. 1 No recent news found in provided results on Altimmune's $225M offering. No recent news found in provided results on Merck teaming up with Google Cloud. Sources: 1. https://www.marketscreener.com/news/novo-nordisk-says-oral-semaglutide-trial-in-children-adolescents-shows-superior-reduction-in-bloo-ce7f59d9de8bf021

Tempero Bio Secures $70M Series B Funding to Advance Substance Use Disorder Treatments

on

Diamyd Medical Announces Governance and Leadership Changes Following Failed Phase 3 Trial

on

Repertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201 for Advanced Solid Tumors

on

Sanofi's Dupixent LCM Strategy Gains Prominence Amid Q1 2026 Success and Patent Defense Plans

on

From Debt to Acceptable Prices: Roche CEO Lists 3 Reasons for Sitting Out Big Pharma M&A Spree

on

Unnamed Pharma Files Citizen Petition Urging FDA to Reform CRL Disclosure Practices

on

Merck's AI Partnership with Google Cloud to Reimagine Commercial Engagement with HCPs

on

Roche's Oral SERD Giredestrant Shows Mixed Clinical Results but Remains Strategically Important

on

Regeneron Among Remaining Holdouts in Trump's Most-Favored-Nation Drug Pricing Deals

on

Live Friday: CDC Ends Universal COVID-19 Vaccine Recommendation – Anti-Vax Shift Under RFK Jr.?

on

BBOT Shakes Up Leadership as RAS Competitors Gain Visibility

on

Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer

on